COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
By H. Siddiqi, Mandeep R. Mehra. The Journal of Heart and Lung Transplantation, 2020
1,564 citations recorded by the source corpus.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/3d7329c02267b61df1635979a74c69ba5698c539
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Iddir
- Alex Brito
- S. Viel
- G. Dingeo
- Sofia Sosa Fernandez Del Campo
- H. Samouda
- Michael R. La Frano
- T. El Jammal
Citations in the corpus
- Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis (2020, background): “This is particularly relevant considering the effects that COVID-19 has on lung function [222].”
- Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions (2020, positive): “SARS-CoV-2) [56,104,105]; (ii) type-I IFN must be administered as soon as possible after infection (ideally before symptom onset) although not in the late phase, because of possible tissue damage [5,52,106,107]; and (iii) although IFN-α inhalation can lower SARS-CoV-2 infection rate”
- The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China (2020, background): “As we know, there are a variety of anti-inflammatory medications, including non steroidal antiinflammatory drugs, glucocorticoids, chloroquine/hydroxychloroquine, immunosuppressants, inflammatory cytokines antagonists (such as IL6R monoclonal antibodies, TNF inhibitors, IL-1 antagonists, janus kinas”